BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8257443)

  • 21. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
    Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
    J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
    Ellis V; Wun TC; Behrendt N; Rønne E; Danø K
    J Biol Chem; 1990 Jun; 265(17):9904-8. PubMed ID: 2161846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type.
    Plow EF; Freaney DE; Plescia J; Miles LA
    J Cell Biol; 1986 Dec; 103(6 Pt 1):2411-20. PubMed ID: 3023400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
    Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
    Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.
    Ellis V; Danø K
    J Biol Chem; 1993 Mar; 268(7):4806-13. PubMed ID: 8444857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
    EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase.
    Kilpatrick LM; Harris RL; Owen KA; Bass R; Ghorayeb C; Bar-Or A; Ellis V
    Blood; 2006 Oct; 108(8):2616-23. PubMed ID: 16794252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis.
    Ellis V; Behrendt N; Danø K
    Methods Enzymol; 1993; 223():223-33. PubMed ID: 8271955
    [No Abstract]   [Full Text] [Related]  

  • 34. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
    Wilhelm S; Wilhelm O; Schmitt M; Graeff H
    Biol Chem Hoppe Seyler; 1994 Sep; 375(9):603-8. PubMed ID: 7840902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
    Baker MS; Liang XM; Doe WF
    Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.
    Zhang L; Strickland DK; Cines DB; Higazi AA
    J Biol Chem; 1997 Oct; 272(43):27053-7. PubMed ID: 9341144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
    Ellis V; Behrendt N; Danø K
    J Biol Chem; 1991 Jul; 266(19):12752-8. PubMed ID: 1829461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
    Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.